• William C. Wirshing
  • Donna Ames
  • Stephen R. Marder
  • Tara Hicks-Gray


Schizophrenia is a major psychiatric illness whose definition has varied with respect to both time and country. Thus, the “schizophrenia” referred to in the American literature of the late 1960s was different from that defined by the British psychiatric profession of the same era and different also from the accepted definitions in the United States today. This evolution of the schizophrenia construct makes it problematic to apply the literature from disparate places and eras to the modern schizophrenia patient.


Psychotic Symptom Schizophrenic Patient Violent Behavior Chronic Schizophrenia Neurologic Soft Sign 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Addad, M., Benezech, M., Bourgeois, M., & Yesavage, J. (1981). Criminal acts among schizophrenics in French mental hospitals. Journal of Nervous and Mental Disease, 169, 289–293.PubMedCrossRefGoogle Scholar
  2. Arana, G. W, Ornstein, M. L., Kanter, E, Friedman, H. L., Greenblatt, D. J., & Shader, R. I. (1986). The use of benzodiazepines for psychotic disorders: A literature review and preliminary clinical findings. Psychopharmacology Bulletin, 22, 77–87.PubMedGoogle Scholar
  3. Atsmon, A., Blum, I., Wijsenbeek, H., Maoz, B., Steiner, M., & Ziegelman, G. (1971). Short-term effects of adrenergic-blocking agents in a small group of psychotic patients: Preliminary clinical observations. Psychiatria, Neurologia, Neurochirurgia,74,251–258.Google Scholar
  4. Baldessarini, R. J., Cohen, B. M., & Teicher, M. H. (1988). Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Archives of General Psychiatry, 45, 79–90.PubMedCrossRefGoogle Scholar
  5. Barber, J. W., Hundley, P., Kellogg, E., Glick, J. L., Godleski, L., Kerler, R., & Vieweg, W. V. R. (1988). Clinical and demographic characteristics of 15 patients with repetitively assaultive behavior. Psychiatric Quarterly,59, 213–224.PubMedCrossRefGoogle Scholar
  6. Beisser, A. R., & Blanchette, J. E. (1961). A study of suicides in a mental hospital. Diseases of the Nervous System, 22, 365–369.PubMedGoogle Scholar
  7. Benezech, M., Bourgeois, M., & Yesavage, J. (1980). Violence in the mentally ill: A study of 547 patients at a French hospital for the criminally insane. Journal of Nervous and Mental Disease, 168,698–700.PubMedCrossRefGoogle Scholar
  8. Biederman, J., Lerner, Y., & Belmaker, R. H. (1979). Combination of lithium carbonate and haloperidol in schizoaffective disorder: A controlled study. Archives of General Psychiatry, 36, 327–333.PubMedCrossRefGoogle Scholar
  9. Blackburn, R. (1968). Emotionality, extraversion and aggression in paranoid and nonparanoid schizophrenic offenders. British Journal of Psychiatry, 114, 1301–1302.PubMedCrossRefGoogle Scholar
  10. Bowers, M. B., & Astrachan, B. M. (1967). Depression in acute schizophrenic psychosis. American Journal of Psychiatry, 123, 976–979.PubMedGoogle Scholar
  11. Breier, A., & Astrachan, B. M. (1984). Characterization of schizophrenic patients who commit suicide. American Journal of Psychiatry, 141, 206–209.PubMedGoogle Scholar
  12. Campbell, R., & Simpson, G. M. (1986). Alternative approaches in the treatment of psychotic agitation. Psychosomatics, 27, 23–26.PubMedCrossRefGoogle Scholar
  13. Carone, B. J., Harrow, M., & Westermeyer, J. E (1991). Posthospital course and outcome in schizophrenia. Archives of General Psychiatry, 48, 247–253.PubMedCrossRefGoogle Scholar
  14. Cheng, K. K., Leung, C. M., Lo, W. H., & Lam, T. H. (1990). Risk factors of suicide among schizophrenics. Acta Psychiatrica Scandinavica, 81, 220–224.PubMedCrossRefGoogle Scholar
  15. Cohen, S., Leonard, C. V., Farberow, N. L., & Shneidman, E. S. (1964). Tranquilizers and suicide in the schizophrenic patient. Archives of General Psychiatry, 11, 312–321.PubMedCrossRefGoogle Scholar
  16. Craig, T. J. (1982). Violence among psychiatric inpatients: An epidemiologic study of problems associated with violence among psychiatric inpatients. American Journal of Psychiatry, 139, 1262–1266.PubMedGoogle Scholar
  17. Diamond, R. (1985). Drugs and the quality of life: The patient’s point of view. Journal of Clinical Psychiatry, 42, 636–637.Google Scholar
  18. Docherty, J. P., Van Kammen, D. P., Skis, S. G., & Marder, S. R. (1978). Stages of onset of schizophrenic psychosis. American Journal of Psychiatry, 135, 420–426.PubMedGoogle Scholar
  19. Donlon, P. T., & Blacker, K. H. (1973). Stages of schizophrenia decompensation and reintegration. Journal of Nervous and Mental Disease, 157, 200–208.PubMedCrossRefGoogle Scholar
  20. Drake, R. E., Gates, C., Whitaker, A., & Cotton, P. G. (1985). Suicide among schizophrenics: A review. Comprehensive Psychiatry, 26, 90–100.PubMedCrossRefGoogle Scholar
  21. Drake, R. E., Gates, C., & Cotton, P. G. (1986). Suicide among schizophrenics: A comparison of attempters and completed suicides. British Journal of Psychiatry, 149, 784–787.PubMedCrossRefGoogle Scholar
  22. Dyck, R. J., Bland, R. C., Newman, S. C., & Orn, H. (1988). Suicide attempts and psychiatric disorders in Edmonton. Acta Psychiatrica Scandinavica, 77 (Suppl. 338), 64–71.CrossRefGoogle Scholar
  23. Eichelmann, B. (1987). Neurochemical bases of aggressive behavior. Psychiatric Annals, 17, 371–374.Google Scholar
  24. Farberow, N. L., Shneidman, E. S., & Leonard, C. V. (1961). Suicide among schizophrenic mental hospital patients. In N. L. Farberow & E. S. Shneidman (Eds.), The cry for help (pp. 78–109). New York/Toronto/London: McGraw-Hill Books.Google Scholar
  25. Fouks, L. (1967). Originalite et specificite de la fluphenazine. In Proceedings of the Fifth International Congress of Neuropsychopharmacology (International Congress Series #192, pp. 1128–1134). Amsterdam: Exerpta Medica Foundation.Google Scholar
  26. Greenfield, T. K., McNiel, D. E., & Binder, R. L. (1989). Violent behavior and length of psychiatric hospitalization. Hospital and Community Psychiatry, 40, 809–814.PubMedGoogle Scholar
  27. Greilsheimer, H., & Groves, J. E. (1979). Male genital self-mutilation. Archives of General Psychiatry, 36, 441–446.PubMedCrossRefGoogle Scholar
  28. Gundlach, R., Engelhardt, D. M., Hankoff, L., Paley, H., Rudorfer, L., & Bird, E. (1966). A double-blind outpatient study of diazepam (Valium) and placebo. Psychopharmacology, 9, 81–92.CrossRefGoogle Scholar
  29. Hakola, H. P. A., & Laulumaa, V. A. (1982, June 12). Carbamazepine in treatment of violent schizophrenics. Lancet, p. 1358.Google Scholar
  30. Herrera, J. N., Sramek, J. J., Costa, J. F., Roy, S., Heh, C. W., & Nguyen, B. N. (1988). High potency neuroleptics and violence in schizophrenia. Journal of Nervous and Mental Disease, 176, 558–561.PubMedCrossRefGoogle Scholar
  31. Hirschowitz, J., Casper, R., & Garver, D. L. (1980). Lithium response in good prognosis schizophrenia. American Journal of Psychiatry, 137, 916–920.PubMedGoogle Scholar
  32. Hollister, L. E., Bennett, J. L., Kimbell, I., Jr., Savage, C., & Overall, J. E. (1963). Diazepam in newly admitted schizophrenics. Diseases of the Nervous System, 24, 746–750.PubMedGoogle Scholar
  33. Hussar, A. E. (1962). Effect of tranquilizers on medical morbidity and mortality in a mental hospital. Journal of the American Medical Association, 179, 682–686.PubMedCrossRefGoogle Scholar
  34. Jimerson, D. C., Van Kammen, D. P, Post, R. M., Docherty, J. P., & Bunney, W. E., Jr. (1982). Diazepam in schizophrenia: Preliminary double-blind trial. American Journal of Psychiatry, 139, 489–491.PubMedGoogle Scholar
  35. Johnson, D. A. W (1981). Studies of depressive symptoms in schizophrenia: I. The prevalence of depression and its possible causes. British Journal of Psychiatry, 139, 89–101.PubMedCrossRefGoogle Scholar
  36. Kahn, E. M., Schulz, S. C., Perel, J. M., & Alexander, J. E. (1990). Change in haloperidol level due to carbamazepine: A complicating factor in combined medication for schizophrenia. Journal of Clinical Psychopharmacology, 10, 54–57.PubMedCrossRefGoogle Scholar
  37. Kane, J., Honigfeld, G., Singer, J., Meltzer, H., & the Clozaril Collaborative Study Group. (1988). Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45, 789–796.PubMedCrossRefGoogle Scholar
  38. Kaplan, H. I., & Sadock, B. J. (Eds.). (1989). Comprehensive textbook of psychiatry (Vol. 5). Baltimore: Williams & Wilkins.Google Scholar
  39. Karson, C., & Bigelow, L. B. (1987). Violent behavior in schizophrenic inpatients. Journal of Nervous and Mental Disease, 175, 161–164.PubMedCrossRefGoogle Scholar
  40. Karson, C. N., Weinberger, D. R., Llewellyn, B., & Wyatt, R. J. (1982). Clonazepam treatment of chronic schizophrenia: Negative results in a double-blind, placebo-controlled trial. American Journal of Psychiatry, 139, 1627–1628.PubMedGoogle Scholar
  41. Keats, M. M., & Mukherjee, S. (1988). Antiaggressive effect of adjunctive clonazepam in schizophrenia-Associated with seizure disorder. Journal of Clinical Psychiatry, 49, 117–118.PubMedGoogle Scholar
  42. Keepers, G. A., Clappison, V. J., & Casey, D. E. (1983). Initial anticholinergic prophylaxis for neurolepticinduced extrapyramidal syndromes. Archives of General Psychiatry, 40, 1113–1117.PubMedCrossRefGoogle Scholar
  43. Kellner, R., Wilson, R. M., Muldawer, M. D., & Pathak, D. (1975). Anxiety in schizophrenia: Responses to chlordiazepoxide in an intensive design study. Archives of General Psychiatry, 32, 1246–1254.PubMedCrossRefGoogle Scholar
  44. Kidron, R., Averbuch, I., Klein, E., & Belmaker, R. H. (1985). Carbamazepine-induced reduction of blood levels of haloperidol in chronic schizophrenia. Biological Psychiatry, 20, 219–222.PubMedCrossRefGoogle Scholar
  45. Klein, D. F., & Davis, J. M. (1969). Diagnosis and drug treatment of psychiatric disorders. Baltimore: Williams & Wilkins.Google Scholar
  46. Klein, E., Bental, E., Lerer, B., & Belmaker, R. H. (1984). Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses: A controlled study. Archives of General Psychiatry, 41, 165–170.PubMedCrossRefGoogle Scholar
  47. Krakowski, M., Volavka, J., & Brizer, D. (1986). Psychopathology and violence: A review of literature. Comprehensive Psychiatry, 27,131–148.PubMedCrossRefGoogle Scholar
  48. Krakowski, M., Convit, A., & Volavka, J. (1988). Patterns of inpatient assaultiveness: Effect of neurological impairment and deviant family environment on response to treatment. Neuropsychiatry, Neuropsychology, and Behavioral Neurology, 1, 21–29.Google Scholar
  49. Lanzkron, J. (1963). Murder and insanity: A survey. American Journal of Psychiatry, 119, 754–758.Google Scholar
  50. Lemus, C. Z., Lieberman, J. A., Johns, C. A., Pollack, S., Bookstein, P., & Cooper, T. B. (1990). CSF 5-hydroxy-indoleacetic acid levels and suicide attempts in schizophrenia. Biological Psychiatry, 27, 926–929.PubMedCrossRefGoogle Scholar
  51. Levy, A. B., Kurtz, N., & Kling, A. S. (1984). Association between cerebral ventricular enlargement and suicide attempts in chronic schizophrenia. American Journal of Psychiatry, 141, 438–439.PubMedGoogle Scholar
  52. Levy, S., & Southcombe, R. H. (1953). Suicide in a state hospital for the mentally ill. Journal of Nervous and Mental Disease, 117, 504–514.PubMedCrossRefGoogle Scholar
  53. Lindstrom, L. H., & Persson, E. (1980). Propranolol in chronic schizophrenia: A controlled study in neuroleptictreated patients. British Journal of Psychiatry, 137, 126–130.PubMedCrossRefGoogle Scholar
  54. Lingjaerde, O. (1982). Effect of the benzodiazepine derivative estazolam in patients with auditory hallucinations: A multicentre double-blind, cross-over study. Acta Psychiatrica Scandinavica, 65, 339–354.PubMedCrossRefGoogle Scholar
  55. Lion, J. R., & Pasternak, S. A. (1973). Countertransference reactions to violent patients. American Journal of Psychiatry, 130, 207–210.PubMedGoogle Scholar
  56. Luchins, D. J. (1984). Carbamazepine in violent non-epileptic schizophrenics. Psychopharmacology Bulletin, 20 569–571.PubMedGoogle Scholar
  57. MacKinnon, B. L. (1977). Postpsychotic depression and the need for personal significance. American Journal of Psychiatry. 134, 427–429.PubMedGoogle Scholar
  58. Madden, D. J., Lion, J. R., & Penna, M. W. (1976). Assaults on psychiatrists by patients. American Journal of Psychiatry, 133, 422–425.PubMedGoogle Scholar
  59. Manscheck, T. C., & Ames, D. (1984). Neurologic features and psychopathology in schizophrenic disorders. Biological Psychiatry, 19, 703–719.Google Scholar
  60. Marder, S. R., Van Putten, T., Mintz, J., McKenzie, J., Labell, M., Faltico, G., & May, P. R. A. (1984). Costs and benefits of two doses of fluphenazine. Archives of General Psychiatry, 41,1025–1029.PubMedCrossRefGoogle Scholar
  61. McGlashan, T. H., & Carpenter, W. T. (1976). An investigation of the postpsychotic depressive syndrome. American Journal of Psychiatry, 133,14–19.Google Scholar
  62. Myers, D. H., Campbell, P. L., Cocks, N. M., Flowerdew, J. A., & Muir, A. (1981). A trial of propranolol in chronic schizophrenia. British Journal of Psychiatry, 139,118–121.PubMedCrossRefGoogle Scholar
  63. Myers, K. M., & Dunner, D. L. (1984). Self and other directed violence on a closed acute-care ward. Psychiatric Quarterly, 56, 178–188.Google Scholar
  64. Neppe, V. M. (1983). Carbamazepine as adjunctive therapy in nonepileptic chronic inpatients with EEG temporal lobe abnormalities. Journal of Clinical Psychiatry, 44, 326–331.PubMedGoogle Scholar
  65. Neppe, V. M. (1988). Carbamazepine in nonresponsive psychosis. Journal of Clinical Psychiatry, 49, 22–28.PubMedGoogle Scholar
  66. Ninan, P. T., Van Kammen, D. P., Scheinin, M., Linnoila, M., Bunney, W. E., Jr., & Goodwin, E K. (1984). CSF 5-hydroxyindoleacetic acid levels in suicidal schizophrenic patients. American Journal of Psychiatry, 141, 566–569.PubMedGoogle Scholar
  67. Nyman, A. K., & Jonsson, H. (1986). Patterns of self-destructive behaviour in schizophrenia. Acta Psychiatrica Scandinavica, 73, 252–262.PubMedCrossRefGoogle Scholar
  68. Oltman, J. E., & Friedman, S. (1941). A psychiatric study of one hundred criminals-with particular reference to the psychological determinants of crime. Journal of Nervous and Mental Disease, 93, 16–41.CrossRefGoogle Scholar
  69. Pearson, M., Wilmot, E., & Padi, M. (1986). A study of violent behavior among in-patients in a psychiatric hospital. British Journal of Psychiatry, 149, 232–235.PubMedCrossRefGoogle Scholar
  70. Peet, M., Bethell, M. S., Coates, A., Khamnee, A. K., Hall, P., Cooper, S. J., King, D. J., & Yates, R. A. (1981). Propranolol in schizophrenia. I. Comparison of propranolol, chlorpromazine and placebo. British Journal of Psychiatry,139,105–111.PubMedCrossRefGoogle Scholar
  71. Piacente, G. J. (1986). Aggression. Neuropsychiatry, 9, 329–339.Google Scholar
  72. Planansky, K., & Johnston, R. (1971). Occurrence and characteristics of suicidal preoccupation and acts in schizophrenia. Acta Psychiatrica Scandinavica, 47, 473–483.PubMedCrossRefGoogle Scholar
  73. Planansky, K., & Johnston, R. (1977). Homicidal aggression in schizophrenic men. Acta Psychiatrica Scandinavica, 55, 65–73.PubMedCrossRefGoogle Scholar
  74. Pollock, H. M. (1938). Is the paroled patient a menace to the community? The Psychiatric Quarterly, 12, 236–244.Google Scholar
  75. Pugh, C. R., Steinert, J., & Priest, R. G. (1983). Propranolol in schizophrenia: A double blind, placebo controlled trial of propranolol as an adjunct to neuroleptic medication. British Journal of Psychiatry, 143,151–155.PubMedCrossRefGoogle Scholar
  76. Quitkin, E, Rifkin, A., & Klein, D. E (1975). Very high dosage vs. standard dosage fluphenazine in schizophrenia: Double-blind study of nonchronic treatment-refractory patients. Archives of General Psychiatry, 32,1276–1281.PubMedCrossRefGoogle Scholar
  77. Quitkin, F, Rifkin, A., & Klein, D. E (1976). Neurologic soft signs in schizophrenia and character disorders. Archives of General Psychiatry, 33, 845–853.PubMedCrossRefGoogle Scholar
  78. Rada, R. T., & Donlon, P. T. (1975). Depression and the acute schizophrenic process. Psychosomatics, 16, 116–119.PubMedGoogle Scholar
  79. Rappeport, J. R., & Lassen, G. (1965). Dangerousness-Arrest rate comparisons of discharged patients and the general population. American Journal of Psychiatry,121,776–783.PubMedGoogle Scholar
  80. Rennie, T. (1939). Follow-up study of five hundred patients with schizophrenia admitted to the hospital from 1913 to 1923. Archives of Neurology, 42, 877–891.Google Scholar
  81. Rifkin, A., & Siris, S. (1987). Drug treatment of acute schizophrenia. In H. Y. Meltzer (Ed.), Psychopharmacology: The third generation of progress (pp. 1095–1101). New York: Raven Press.Google Scholar
  82. Rifkin, A., Quitkin, E, & Klein, D. E (1975). Akinesia, a poorly recognized drug-induced extrapyramidal behavioral disorder. Archives of General Psychiatry, 32, 672–674.CrossRefGoogle Scholar
  83. Robertson, G. (1988). Arrest patterns among mentally disordered offenders. British Journal of Psychiatry, 153, 313–316.PubMedCrossRefGoogle Scholar
  84. Rollin, H. R. (1965). Unprosecuted mentally abnormal offenders. British Medical Journal, 1, 831–835.PubMedCrossRefGoogle Scholar
  85. Rossi, A. M., Jacobs, M., Monteleone, M., Olsen, R., Surber, R. W., Winkler, E. L., & Wommack, A. (1986). Characteristics of psychiatric patients who engage in assaultive or other fear-inducing behaviors. Journal of Nervous and Mental Disease,174,154–160.CrossRefGoogle Scholar
  86. Roth, S. (1970). The seemingly ubiquitous depression following acute schizophrenic episodes, a neglected area of clinical discussion. American Journal of Psychiatry, 127, 91–98.Google Scholar
  87. Roy, A. (1982). Suicide in chronic schizophrenia. British Journal of Psychiatry, 141, 171–177.PubMedCrossRefGoogle Scholar
  88. Roy, A. (1986). Depression, attempted suicide, and suicide in patients with chronic schizophrenia. Psychiatric Clinics of North America, 9, 193–206.Google Scholar
  89. Roy, A., Mazonson, A., & Pickar, D. (1984). Attempted suicide in chronic schizophrenia. British Journal of Psychiatry, 144, 303–306.PubMedCrossRefGoogle Scholar
  90. Roy, A., Ninan, P, Mazonson, A., Pickar, D., Van Kammen, D., Linnoila, M., & Paul, S. M. (1985). CSF monoamine metabolites in chronic schizophrenic patients who attempt suicide. Psychological Medicine, 15, 335–340.PubMedCrossRefGoogle Scholar
  91. Salama, A. A. (1988). Depression and suicide in schizophrenic patients. Suicide and Life-Threatening Behavior, 18, 379–384.PubMedGoogle Scholar
  92. Salzman, C., Green, A. I., Rodriguez-Villa, E, & Jaskiw, G. I. (1986). Benzodiazepines combined with neuroleptics for management of severe disruptive behavior. Psychosomatics, 27, 17–21.PubMedCrossRefGoogle Scholar
  93. Semrad, E. V. (1966). Long-term therapy of schizophrenia. In E. L. Usdin (Ed.), Psychoneuroses and schizophrenia (pp. 155–156). Philadelphia: J. B. Lippincott.Google Scholar
  94. Shader, R. I., Jackson, A. H., Harmatz, J. S., & Appelbaum, P S. (1977). Patterns of violent behavior among schizophrenic inpatients. Diseases of the Nervous System, 38, 13–16.PubMedGoogle Scholar
  95. Shaffer, J. W., Perlin, S., Schmidt, C. W, & Stephens, J. H. (1974). Prediction of suicide in schizophrenia. Journal of Nervous and Mental Disease, 159, 349–355.PubMedCrossRefGoogle Scholar
  96. Sheppard, G. P (1979). High-dose propranolol in schizophrenia. British Journal of Psychiatry, 134, 470–476.PubMedCrossRefGoogle Scholar
  97. Silverman, D. (1943). Psychoses in criminals: A study of five hundred psychotic prisoners. Journal of Criminal Psychopathology, 4, 703–723.Google Scholar
  98. Simpson, G. M., Varga, E., & Haber, E. J. (1976). Psychotic exacerbations produced by neuroleptics. Diseases of the Nervous System, 37, 367–369.PubMedGoogle Scholar
  99. Siris, S. G., Van Kammen, D. P., & Docherty, J. P (1978). Use of antidepressant drugs in schizophrenia. Archives of General Psychiatry, 35, 1368–1377.PubMedCrossRefGoogle Scholar
  100. Small, J. G., Kellams, J. J., Milstein, V., & Moore, J. (1975). Placebo-controlled study of lithium combined with neuroleptics in chronic schizophrenic patients. American Journal of Psychiatry, 132, 1315–1317.PubMedGoogle Scholar
  101. Sramek, J., Herrera, J., Costa, J., Heh, C., Tran-Johnson, T., & Simpson, G. (1988). A carbamazepine trial in chronic, treatment-refractory schizophrenia. American Journal of Psychiatry, 145, 748–750.PubMedGoogle Scholar
  102. Tardiff, K. (1984). Characteristics of assaultive patients in private hospitals. American Journal of Psychiatry, 141, 1232–1235.PubMedGoogle Scholar
  103. Tardiff, K. (1989). Concise guide to assessment and management of violent patients. Washington, DC: APA Press.Google Scholar
  104. Tardiff, K., & Sweillam, A. (1979). The relation of age to assaultive behavior in mental patients. Hospital and Community Psychiatry, 30, 709–711.PubMedGoogle Scholar
  105. Tardiff, K., & Sweillam, A. (1980). Assault, suicide, and mental illness. Archives of General Psychiatry, 37, 164–169.PubMedCrossRefGoogle Scholar
  106. Tardiff, K., & Sweillam, A. (1982). Assaultive behavior among chronic inpatients. American Journal of Psychiatry, 139, 212–215.PubMedGoogle Scholar
  107. Taylor, P J., & Gunn, J. (1984, June 30). Violence and psychosis. I. Risk of violence among psychotic men. British Medical Journal, 288 (Abstracts from Clinical Research 1945–1952).Google Scholar
  108. Teicher, M. H., & Baldessarini, R. J. (1985). Selection of neuroleptic dosage. Archives of General Psychiatry, 42, 636–637.PubMedCrossRefGoogle Scholar
  109. Tennent, G., Loucas, K., Fenton, G., & Fenwick, P (1974). Male admissions to Broadmoor Hospital. British Journal of Psychiatry, 125, 44–50.CrossRefGoogle Scholar
  110. ’Ricker, G. J., Campion, E. W, & Silberfarb, P M. (1975). Sensorimotor functions and cognitive disturbance in psychiatric patients. American Journal of Psychiatry, 132, 17–21.Google Scholar
  111. Van Praag, H. M. (1983, October 22). CSF 5-HIAA and suicide in nondepressed schizophrenics. Lancet, pp. 977–978.Google Scholar
  112. Van Praag, H. M. (1986). (Auto) aggression and CSF 5-HIAA in depression and schizophrenia. Psychopharmacology Bulletin, 22, 669–673.PubMedGoogle Scholar
  113. Van Putten, T. (1975). The many faces of akathisia. Comprehensive Psychiatry, 16, 43–47.PubMedCrossRefGoogle Scholar
  114. Van Putten, T., & May, P R. A. (1978). Akinetic depression in schizophrenia. Archives of General Psychiatry, 35, 1101–1107.PubMedCrossRefGoogle Scholar
  115. Van Putten, T., Marder, S. R., May, P. R. A., Poland, R. E., & O’Brien, R. P (1985). Plasma levels of haloperidol and clinical response. Psychopharmacology Bulletin, 21, 69–72.PubMedGoogle Scholar
  116. Van Putten, T., Mutalipassi, L. R., & Malkin, M. D. (1974). Phenothiazine-induced decompensation. Archives of General Psychiatry, 30, 102–105.PubMedCrossRefGoogle Scholar
  117. Virkkunen, M. (1974). Observations on violence in schizophrenia. Acta Psychiatrica Scandinavica, 50,145–151.PubMedGoogle Scholar
  118. Volavka, J., & Krakowski, M. (1989). Schizophrenia and violence. Psychological Medicine,19, 559–562.PubMedCrossRefGoogle Scholar
  119. Warnes, H. (1968). Suicide in schizophrenics. Disease of the Nervous System, 29, 35–40.Google Scholar
  120. Wilkinson, G., & Bacon, N. A. (1984). A clinical and epidemiological survey of parasuicide and suicide in Edinburgh schizophrenics. Psychological Medicine, 14, 899–912.PubMedCrossRefGoogle Scholar
  121. Winchel, R. M., & Stanley, M. (1991). Self-injurious behavior: A review of the behavior and biology of self-mutilation. American Journal of Psychiatry, 148,306–317.PubMedGoogle Scholar
  122. Winokur, G., & Tsuang, M. (1975). The Iowa 500: Suicide in mania, depression, and schizophrenia. American Journal of Psychiatry, 132,650–651.PubMedGoogle Scholar
  123. Wong, S. E., Woolsey, J. E., Innocent, A. J., & Liberman, R. P. (1988). Behavior treatment of violent psychiatric patients. Psychiatric Clinics of North America, 11, 569–580.PubMedGoogle Scholar
  124. Yarden, P. E. (1974). Observations on suicide in chronic schizophrenics. Comprehensive Psychiau y, 15,325–333.CrossRefGoogle Scholar
  125. Yesavage, J. A. (1982). Inpatient violence and the schizophrenic patient: An inverse correlation between danger-related events and neuroleptic levels. Biological Psychiatry, 17, 1331–1337.PubMedGoogle Scholar
  126. Yesavage, J. A. (1983). Inpatient violence and the schizophrenic patient: A study of Brief Psychiatric Rating Scale scores and inpatient behavior. Acta Psychiatrica Scandinavica, 67, 353–357.PubMedCrossRefGoogle Scholar
  127. Yesavage, J. A., Werner, P. D., Becker, J., Holman, C., & Mills, M. (1981). Inpatient evaluation of aggression in psychiatric patients. Journal of Nervous and Mental Disease, 169,299–302.PubMedCrossRefGoogle Scholar
  128. Yorkston, N. J., Zaki, S. A., Pitcher, D. R., Gruzelier, J. H., Hollander, D., & Sergeant, H. G. S. (1977, September 17). Propranolol as an adjunct to the treatment of schizophrenia. Lancet, pp. 575–578.Google Scholar
  129. Zitrin, A., Hardesty, A. S., Burdock, E. I., & Drossman, A. K. (1976). Crime and violence among mental patients. American Journal of Psychiatry, 133,142–149.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • William C. Wirshing
    • 1
  • Donna Ames
    • 1
  • Stephen R. Marder
    • 1
  • Tara Hicks-Gray
    • 1
  1. 1.Department of Psychiatry and Biobehavioral SciencesUCLA School of Medicine, and West Los Angeles Veterans Affairs Medical CenterLos AngelesUSA

Personalised recommendations